Clasp Therapeutics
NEWS
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
Clasp Therapeutics announced Wednesday that the Series A funding, which was led in part by Novo Holdings, will support development of its T cell engagers for highly specific tumor targeting.
JOBS
IN THE PRESS